REG - BSF Enterprise PLC - 3D Bio-Tissues receives €100,000 grant

BSF EnterpriseAnnouncement

27/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221027:nRSa3090Ea&default-theme=true

RNS Number : 3090E  BSF Enterprise PLC  27 October 2022

 

27 October 2022

 

BSF Enterprise PLC

("BSF" or the "Company")

3D Bio-Tissues receives €100,000 grant

BSF Enterprise, an investment company focused on unlocking the next generation
of biotech solutions and the development of lab-grown tissues, is pleased to
announce that its 100% owned subsidiary, 3D Bio-Tissues (3DBT), has been
awarded a €100,000 grant to build upon the current capabilities of its
proprietary serum-free media, City-mix™.

 

The grant was awarded by leading food innovation organisations, EIT Food,
co-founded by the European Union, in partnership with the Good Food Institute.
EIT Food's aim is to drive the production of cultivated meat, reduce the cost
of cultivated meat production, and accelerate its commercialisation.

 

City-mix™ is an animal-free cell growth agent for culturing skin, muscle and
fat cells for use in cultivated meat and leather production. It aims to
maximise the effectiveness of using animal-free culture media, reduce the
reliance on animal protein components in meat products, and lower the cost of
production for manufacturers.

 

More broadly, cultivated meat has the potential to be far less
resource-intensive, decreasing methane emissions, deforestation, biodiversity
loss, water use, water pollution, antibiotic resistance, and foodborne
illnesses. These products are identical to the beef, pork, chicken, and
seafood that people enjoy eating today - but grown directly from animal cells
instead of animals. A recent study by CE Delft - the first ever to be based on
data from cultivated meat companies - found that cultivating meat from cells
could cut the climate impact by up to 92 per cent, reduce air pollution by up
to 93 per cent, and use up to 95 per cent less land and 78 per cent less water
compared with farming animals.

 

Today's announcement marks another important milestone ahead of 3DBT unveiling
the UK's first 100% lab-grown fillet in the next few months.

Che Connon, Chief Executive of 3D-Bio Tissues, said: "We are honoured to
receive this award. 3D Bio-Tissues is at the forefront of cultivated meat
innovation, and we believe our technology has the potential to create a real
impact on this market and improve the lives of millions of people around the
world. This grant is a strong endorsement of our team and our work from a
range of prestigious groups in our sector."

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                      Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                             0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                             020 3757 6882

 Elisabeth Cowell                        BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGUBDGGGDDGDR